Regulating the relationship between physicians and pharmaceutical companies: a qualitative and descriptive analysis of the impact of Israeli legislation
Abstract Background The Israeli National Health Insurance Law was amended in 2010 to require the disclosure of payments above 2500 NIS from pharmaceutical companies (PCs) to medical personnel and organizations. We examined if the law had an impact on the relationship between physicians in the Israel...
Main Authors: | Rachel Nissanholtz-Gannot, Ariel Yankellevich |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-09-01
|
Series: | Israel Journal of Health Policy Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13584-017-0170-3 |
Similar Items
-
Barriers in implementing the dying patient law: the Israeli experience - a qualitative study
by: Avi Zigdon, et al.
Published: (2020-12-01) -
ANALYSIS OF PHARMACEUTICAL COMPANIES’ ACTIVITIES THAT ARE DIRECTED TO PHYSICIANS IN EGYPT
by: M. M. Bahlol, et al.
Published: (2016-03-01) -
Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
by: Yurie Kobashi, et al.
Published: (2019-10-01) -
Analysis of the legislation of the Republic of Moldova in terms of pharmaceutical security
by: Valentina Buliga
Published: (2017-02-01) -
Monitoring quality in Israeli primary care: The primary care physicians' perspective
by: Nissanholtz-Gannot Rachel, et al.
Published: (2012-06-01)